– USA, MA – Moderna, Inc. (Nasdaq: MRNA), a clinical-stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Dr Sandra Horning, M.D. has been nominated to join its Board of Directors effective as of April 29, 2020, the date of the Company’s annual meeting of stockholders.
Dr. Horning has been nominated as a Class II Director and will serve as a member of the Product Development Committee of the Board.
“As we continue to build Moderna, we seek to bolster our board with industry leaders from companies at the cutting edge of science with experience in bringing transformative medicines to patients,” said Noubar Afeyan, Ph.D., Co-Founder and Chairman of Moderna, and CEO of Flagship Pioneering. “Sandra is a true visionary with a highly distinguished career and we believe she will bring important expertise to advancing Moderna’s progress.”
“As Moderna approaches more advanced stages of development across our clinical programs, we sought a director with deep experience bringing new medicines in multiple therapeutic areas to market at a global biopharmaceutical organization. Sandra’s expertise and commitment to patients make her an important addition to our board and in helping to make our vision a reality,” said Stéphane Bancel, CEO. “As a cancer survivor, physician and researcher, Sandra brings a unique perspective, and we look forward to learning from and working with her.”
About Dr Sandra Horning
Dr. Horning is an academic and industry veteran, most recently serving as Chief Medical Officer and Head of Global Product Development at Genentech/Roche (SIX:RO).
Dr. Horning is currently a co-founder and advisor for EQRx, a biotechnology company focused on creating innovative medicines at lower prices and serves on the Board of Directors of Gilead Sciences, Inc. (Nasdaq: GILD). Previously she served as Chief Medical Officer and Head of Global Product Development at Genentech/Roche from 2014 to 2019. Over the course of a decade, she oversaw the approval of 15 new medicines across a variety of diseases, including cancer, multiple sclerosis, influenza and blindness. Prior to joining Genentech, she spent more than 20 years as a Professor of Medicine, Oncology and Blood and Bone Marrow Transplantation at Stanford University School of Medicine, where she remains an Emerita Professor.
She has received numerous awards and recognitions throughout her career – she is the recipient of the Healthcare Businesswomen’s Association 2020 Woman of the Year, 2017 Duane Roth Memorial Award, 2014 Fierce Biotech Top Women in Biotech Award and 2010 Top Women in Bay Area Business Award. She was President of the American Society of Clinical Oncology from 2005-2006 and has served on the editorial boards of several peer-reviewed medical journals, including the Journal of Clinical Oncology, Clinical Cancer Research, Clinical Lymphoma, Leukemia & Lymphoma, the Annals of Internal Medicine and the American Journal of Medicine.
“I am delighted to join the talented team at Moderna and work alongside fellow directors as the company continues to build on its leadership in mRNA science,” said Dr. Horning. “I’ve devoted my life to advancing innovative treatments for patients, and I am excited by the potential of mRNA therapy to prevent and treat a wide range of serious diseases. I look forward to supporting Moderna as it moves into late-stage development and continues to advance its broad mRNA pipeline.”
Dr. Horning received her M.D. from the University of Iowa School of Medicine and completed her post-graduate fellowship in Oncology and Cancer Biology at Stanford University.
About Moderna
Moderna is advancing messenger RNA science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune and inflammatory diseases, independently and with strategic collaborators.
Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca, Plc. (Nasdaq: AZN) and Merck, Inc. (Nasdaq: MRK), as well as the Defense Advanced Research Projects Agency, an agency of the U.S. Department of Defense; the Biomedical Advanced Research and Development Authority, a division of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services. Moderna has been named a top biopharmaceutical employer by Science for the past five years.
For more information: https://www.modernatx.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
